Can brain-MRI embeddings still identify patients?
An unreviewed audit of five encoders found that representations derived from longitudinal scans could still support patient matching and recorded-sex inference. The study tests a defined attacker with auxiliary scans; it does not show a breach of a hospital or identify anyone in the real world.
The short version
3 key points
- 1.The audit used five frozen encoders and two longitudinal datasets: 150 OASIS-2 subjects and 69 MIRIAD subjects, with repeated T1-weighted MRI scans.
- 2.In the authors' strongest tested representation, top-ranked same-patient matching reached 92.05% on OASIS-2 and 99.71% on MIRIAD; performance varied markedly by encoder and dataset.
- 3.The attack assumes access to released embeddings, the public encoder and auxiliary scans. It does not establish that embeddings alone reveal a person's name, or that a hospital release has been exploited.
The answer: replacing scans with embeddings did not remove identity-linked information
Yes, under the conditions tested. The researchers found that several pretrained encoders preserved enough stable information about brain anatomy for an auxiliary scan from the same person to rank above scans from other people. That is a warning against treating a learned numerical representation as automatically anonymous simply because the original image is absent.
The most important qualification is the threat model. The attacker is assumed to possess the released embeddings, know the public feature-extraction pipeline and hold auxiliary MRI scans that may include the same people at different times. The study evaluates whether those records can be linked and, if the auxiliary records also carry names, whether that linkage could support re-identification. The experiment itself used dataset subject labels only to score matches. It did not uncover real identities, enter a clinical system or demonstrate an unauthorised release.
The manuscript was submitted to arXiv on 14 October and has not been peer reviewed. Its authors are affiliated with institutions in Canada and France. They report no new recruitment: the work re-analysed established research datasets. Generative AI was used for language refinement, selected implementation assistance and figures, with the authors stating that outputs and experiments were manually checked.[1]
What was tested
The audit compared five frozen encoders: AnatCL, 3D-Neuro-SimCLR, Brain-MRI-SSL, DINO-ViT and SAM-Med3D. They span three-dimensional and two-dimensional architectures, self-supervised and supervised objectives, and pretraining on brain MRI, broader medical images or natural images. The encoders were not trained on either evaluation dataset and were not designed with patient identification as an objective.
Two longitudinal T1-weighted MRI datasets supplied repeated observations. OASIS-2 contributed 150 subjects, each with two to five sessions over multiple years. MIRIAD contributed 69 subjects and 708 scans, with as many as 12 scans across nine visits and follow-up intervals ranging from about two weeks to two years. These are scans acquired at different times, not repeated copies of a single image. OASIS-2 was already motion-corrected, registered, skull-stripped and intensity-corrected; MIRIAD differed in acquisition and preprocessing.
For every scan in turn, the authors treated its embedding as the query and ranked all other scans by Canberra similarity. The query itself was excluded, and every subject had at least one genuine same-person reference. The reported top-rank metric is therefore the proportion of scans whose nearest eligible reference came from the same dataset subject. A random subject-level guess would be about 0.68% in OASIS-2 and 1.45% in MIRIAD.
A separate random-forest analysis tested whether embeddings predicted the recorded binary sex field. Subjects were kept entirely in either training or held-out test folds so that repeated scans from one person did not leak across the split. Balanced accuracy was used because it gives equal weight to the two recorded categories. This is attribute inference from representation features, not a clinical or biological assessment of gender identity.[1][2]
The results varied, but the highest risks were far above chance
AnatCL produced the highest top-ranked matching result on OASIS-2 at 92.05% and reached 99.71% on MIRIAD. DINO-ViT reached 82.35% and 98.70% respectively. SAM-Med3D was the lowest-risk encoder in both sets, yet its matching result was still 13.94% on OASIS-2 and 89.58% on MIRIAD. The large cross-dataset shifts show why one headline percentage cannot describe every representation or deployment.
A hand-engineered baseline of 15 FreeSurfer anatomical measurements reached 75.00% on OASIS-2 and 99.93% on MIRIAD. That comparison matters: the privacy signal is not necessarily created by a foundation model. Stable brain anatomy can itself be distinctive, and both learned and conventional representations may retain it. The paper therefore supports testing the released artefact, not assuming that a particular model family is uniquely responsible.
Recorded-sex prediction also varied. Brain-MRI-SSL reached balanced accuracy of 90.93% on OASIS-2 and 95.46% on MIRIAD. But performance fell when a classifier trained on one cohort was tested on the other, often approaching chance. That weak cross-dataset transfer suggests that acquisition, preprocessing or cohort-specific factors may contribute to the signal. It does not erase the within-dataset result, but it limits claims about generalisation.[1]
What hospitals, researchers and patients should take from it
A hospital or research consortium should not label an embedding anonymous merely because it cannot be viewed like a scan. Before sharing, teams can test patient linkage and sensitive-attribute inference under realistic auxiliary-data assumptions, document who can obtain the encoder and preprocessing code, and decide whether access controls, contractual limits, aggregation or privacy-preserving transformation are required. The paper's audit is evidence for risk assessment, not a certification method or a legal determination.
For clinicians and data stewards, the practical issue is secondary use. A representation created for segmentation, retrieval or another downstream task may preserve information that task does not need. Minimising exported features, limiting repeated longitudinal records, separating identity-linked reference stores and logging access can reduce opportunity for misuse. Any protection also needs a utility test: removing identity-bearing structure may degrade the clinical or research signal the representation was created to preserve.
For patients, the study does not mean that any released brain embedding can be converted into a name. Linkage requires a pathway to auxiliary scans, and re-identification requires those references to be identity-linked. It does mean that organisations should explain those pathways when describing de-identification and should avoid suggesting that vectorisation by itself makes sensitive imaging safe to publish.[1]
Evidence limits and what would change the assessment
The evidence is bounded to two relatively small longitudinal datasets, five encoders, one image type and one inferred attribute. The models differ at the same time in architecture, training data, objective and preprocessing, so the comparison cannot isolate which design choice caused a result. MIRIAD has many repeated scans per person, increasing the number of genuine references, and its preprocessing differs from OASIS-2. The authors' reduced-scan analysis still found high matching, but dataset effects remain substantial.
Confidence would rise with preregistered replication on independent clinical cohorts, more scanners and institutions, other image modalities and explicit external attackers who do not share the researcher's pipeline knowledge. Studies should compare raw scans, embeddings and protected representations at matched downstream utility, report confidence intervals and test whether attacks survive realistic distribution shift. Peer review and independent reproduction of the released code would also clarify implementation sensitivity.
The assessment would weaken if privacy transformations consistently drove linkage and attribute inference close to chance without materially reducing diagnostic or research performance. It would strengthen if attackers linked embeddings across institutions under realistic access conditions or inferred a wider set of sensitive attributes in external cohorts. For now, the defensible conclusion is narrower: the evaluated embeddings retained measurable, sometimes very strong subject-specific information, so vectorisation alone was not anonymity.[1]
What this means for people
- Patients need accurate explanations of what information may remain in shared imaging representations and who can obtain auxiliary scans.
- Clinicians and research teams should treat embeddings as sensitive data until a context-specific privacy assessment supports a narrower classification.
- Data-protection officers can use linkage and inference audits to test claims, while recognising that technical results do not replace legal analysis.
Global context
Medical-imaging collaborations routinely cross hospitals and borders, while the same public encoders can be reused in many jurisdictions. Privacy law and anonymisation standards differ, but the technical question is shared: what could a motivated party infer when representations, model code and external reference data are combined? Smaller institutions may have less capacity to run these audits, increasing the value of transparent, reproducible evaluation protocols.
What the evidence does not yet show
- This is an unreviewed preprint using existing research datasets, not a reported breach, prospective deployment or patient-outcome study.
- Only 150 OASIS-2 subjects and 69 MIRIAD subjects were included; scanners, cohorts, repeated-scan counts and preprocessing differed.
- The five encoders differ in several dimensions at once, preventing causal attribution to one architecture, objective or training domain.
- Re-identification requires identity-linked auxiliary references; the experiment measured dataset-subject matching and did not recover real-world identities.
- Recorded-sex inference was tested as one binary dataset field and transferred poorly across cohorts for most encoders.
What to watch next
- Peer review and independent reproduction of the feature-extraction, linkage and attribute-inference pipeline.
- External-cohort tests across hospitals, scanners, populations and MRI protocols with realistic attacker access.
- Privacy-preserving representations evaluated jointly for residual leakage and clinically relevant utility.
- Clear institutional policies distinguishing pseudonymisation, de-identification and evidence sufficient to claim anonymity.
Living evidence record
Impact record IAI-0CFM638
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
16 October 2026
Source trail
2 direct sources across 2 source types.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Related-source reporting disclosure
This record analyses 2 linked source records around the same underlying development. The extra records add method, date or context, but they do not by themselves constitute independent replication of every performance claim or predicted outcome.
Evidence trail
Sources used for this report
Links checked 16 October 2026
Research question, topics and regions
Whether embeddings produced by pretrained brain-MRI encoders retain enough subject-specific and demographic information to support patient linkage and attribute inference
Topics: Medical imaging · Patient privacy · Foundation models · Data governance · Biometrics
Regions: Canada · France · United States · United Kingdom
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Watch the background, then check the evidence

The Royal Society
AI-generated illustration · not a video frame
YouTube loads only when you choose. Press play in the player to start. If playback is unavailable, use “Watch on YouTube” below.
Healthcare, culture & human impact · Background explainer
Published 2026-07-01 · 44 min 28 sec
Is this the AI future we want? | The Royal Society
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Source checked 14 October 2026. Check available captions on the publisher’s video page.
The Impact Brief · Free
Keep following the stories that matter to you.
Get our weekday briefing on what changed and why it matters. Choose your topics below.
Continue the story
There’s more to this story
Health & Life Sciences
Can a foundation model track tumours during MR-guided radiotherapy?
On 38 held-out cine-MR sequences, fine-tuned SAM2 variants reduced average boundary and centre errors and ran fast enough for the tested image stream. The work remains a retrospective technical test: it did not steer radiation or measure patient safety.
8 min · 1 source
Health & Life Sciences
Can brain MRI reveal more than BMI?
A peer-reviewed study trained a deep-learning model on 45,702 MRI scans from six cohorts. Brain-derived features tracked BMI and separated several disease groups better than BMI alone—but the disease analysis stayed inside UK Biobank and cannot establish cause, diagnosis or clinical benefit.
9 min · 2 sources
Health & Life Sciences
Does 93.5% Dice make this ovarian-cancer CT AI clinically ready?
No. A two-stage ensemble improved segmentation on a patient-separated TCGA-OV test set, but the study involved only 143 patients, inherited molecular labels at patient level and had no external or prospective clinical validation.
8 min · 2 sources
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.